SLC25A40 Genotype

If your triglycerides run stubbornly high and the pattern shows up across generations of your family, the explanation may not be in your diet or your routine cholesterol panel. It may be written in a single gene that codes for a transporter inside your cells' energy-producing compartments.

SLC25A40 (solute carrier family 25 member 40) is one of the more recently identified genes connected to inherited high triglycerides. Testing it is a research-oriented look at whether a rare, high-impact variant in this gene is contributing to a stubborn lipid pattern that standard tests have not been able to explain.

What This Gene Does

SLC25A40 makes a protein that sits in the inner membrane of mitochondria, the energy-producing compartments inside your cells. Proteins in this family act like specialized doors, ferrying small molecules in and out of the mitochondria so that energy production and fat handling can run smoothly. The SLC25 family has 53 members in humans that move nucleotides, amino acids, fatty acids, ions, and other small molecules across this membrane.

An important caveat: the specific small molecule that SLC25A40 transports has not been worked out in the lab. Its link to triglyceride metabolism is inferred from genetic association in families, not from biochemistry showing exactly what it carries or how. The variant that has been most carefully studied, called p.Tyr125Cys, sits just outside the second helical transmembrane region of the protein and is considered highly disruptive to its function.

Triglyceride Risk

The strongest evidence for SLC25A40 comes from a single large family study. Researchers examined a five-generation European American family of 121 individuals ascertained for familial combined hyperlipidemia (FCH), an inherited condition where multiple types of blood fats run high. They were looking for the genetic cause.

Within this family, a specific rare variant in SLC25A40, c.374A>G (which changes the protein at position 125 from tyrosine to cysteine), was strongly tied to triglyceride levels. Together with a variant in another gene called PLD2, the SLC25A40 variant accounted for 49% of the inherited differences in triglycerides within this specific family. This is a within-family estimate, not a population-level figure. The statistical signal for SLC25A40 alone was very strong (p = 0.0001), meaning the link is highly unlikely to be due to chance within this pedigree.

The same gene was then tested in a broader group of people who had undergone whole-exome sequencing through the Exome Sequencing Project. When all rare, highly conserved coding variants in SLC25A40 were grouped together, the gene showed a modest association with triglyceride levels (p = 0.03). This p-value is modest and would not survive multiple testing correction in a genome-wide context, but it offers some support beyond the original family. Importantly, SLC25A40 has not appeared as a significant hit in subsequent large-scale genome-wide or gene-burden analyses for triglycerides, and independent replication remains limited.

There is also broader context worth knowing. More recent work suggests that familial combined hyperlipidemia is most likely a polygenic trait rather than a single-gene disorder, with no single gene fully explaining the phenotype. The SLC25A40 finding fits into this picture as one rare contributor in one family, not as a sole cause of FCH.

What an Abnormal Result Actually Tells You

This is an emerging research marker, not a standardized clinical test. Carrying a rare disruptive variant in SLC25A40 does not guarantee you will develop high triglycerides, and not carrying one does not protect you from common, lifestyle-driven hypertriglyceridemia. The known evidence covers only a small slice of possible variants in this gene and a small population overall.

What a positive finding can do is offer a possible explanation when triglycerides are persistently high in a family, especially when more established lipid genetic tests, such as familial hypercholesterolemia panels covering LDLR, APOB, and PCSK9, come back clean. It can also signal that other family members may share the same variant and should consider getting their lipids checked carefully.

A One-Time Test

Because SLC25A40 is a gene you are born with, this is a once-in-a-lifetime test. Your result will not change over the years, and there is no need to repeat the genotyping. If a high-impact variant is identified by a screening method like a SNP chip, your clinician may want to confirm the call with a more precise sequencing method, but the underlying genotype itself does not need to be retested.

What does need ongoing monitoring is the downstream phenotype: your triglycerides. If you carry a rare variant linked to high triglycerides, a standard or advanced lipid panel becomes the marker to track. Getting a baseline lipid profile and then retesting at least once a year, or every three to six months if you are making lifestyle or medication changes, gives you the moving picture this genetic test cannot.

What to Do With an Unexpected Result

If a rare variant in SLC25A40 is found, the next steps are not about retesting the gene. They are about building out the picture around it. A full lipid workup that goes beyond standard cholesterol, including triglyceride patterns over time and an ApoB (apolipoprotein B, a measure of harmful particle count) test, helps quantify the actual cardiovascular risk that the genotype suggests.

A consultation with a lipidologist or a genetic counselor is worth considering. They can help interpret the variant in the context of your family history, suggest which biological relatives might benefit from testing, and decide whether more aggressive lipid management is warranted earlier in life than would otherwise be standard.

Limits of the Current Evidence

Most of what is known about SLC25A40 comes from one large pedigree plus a modest supportive gene-level signal in a broader exome dataset, and the gene has not been independently replicated in large-scale population studies. Common polymorphisms in this gene have not been mapped to outcomes, and there are no large prospective cohort studies, no hazard ratios for cardiovascular events, and no established cutpoints for when to act. The clinical utility of testing in the general population is plausible but unproven.

This is a marker for someone who wants to explore a possible inherited explanation for a stubborn lipid pattern, not someone looking for a definitive risk score. Treat the result as one piece of a larger investigation rather than a verdict.